重组Anti-Aurora B抗体[EP1009Y]
Anti-Aurora B antibody [EP1009Y]
- BOND RX™ Validated
- RabMAb
- Recombinant
- 了解详情
4
(1 Review)
|
(32 Publications)
Rabbit Recombinant Monoclonal Aurora B antibody. Suitable for ICC/IF, IP, WB, IHC-P, Flow Cyt (Intra) and reacts with Human samples. Cited in 32 publications.
查看别名
AIK2, AIM1, AIRK2, ARK2, STK1, STK12, STK5, AURKB, Aurora kinase B, Aurora 1, Aurora- and IPL1-like midbody-associated protein 1, Aurora/IPL1-related kinase 2, STK-1, Serine/threonine-protein kinase 12, Serine/threonine-protein kinase 5, Serine/threonine-protein kinase aurora-B, AIM-1, ARK-2, Aurora-related kinase 2
- IHC-P
Lab
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (AB45145)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human endometrium carcinoma tissue sections labeling Aurora B with purified ab45145 at 1/200 dilution (1.35 µg/mL). Heat mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0). The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
- Flow Cyt (Intra)
Lab
Flow Cytometry (Intracellular) - Anti-Aurora B antibody [EP1009Y] (AB45145)
Intracellular Flow Cytometry analysis of HeLa (Human cervix adenocarcinoma epithelial cell) cells labeling Aurora B with Purified ab45145 at 1/300 dilution (0.1 μg/ml) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488 ,ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Left). Unlabeled control - /.
- ICC/IF
Lab
Immunocytochemistry/ Immunofluorescence - Anti-Aurora B antibody [EP1009Y] (AB45145)
Immunocytochemistry analysis of HeLa (Human cervix adenocarcinoma epithelial cell) cells labeling Aurora B with Purified ab45145 at 1 : 50 dilution (5.4 µg/ml). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1 : 200 (2.5 µg/ml). Goat anti rabbit IgG (Alexa Fluor® 488,ab150077) was used as the secondary antibody at 1 : 1000 (2 µg/ml) dilution. DAPI (blue) was used as nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.
- IP
Lab
Immunoprecipitation - Anti-Aurora B antibody [EP1009Y] (AB45145)
Purified ab45145 at 1/20 dilution (1μg) immunoprecipitating Aurora B in HeLa whole cell lysate.
Lane 1 (input) : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10μg
Lane 2 (+) : ab45145 + HeLa whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab45145 in HeLa whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 39 kDa
All lanes:
Immunoprecipitation - Anti-Aurora B antibody [EP1009Y] (ab45145)
Predicted band size: 39 kDa
false
- WB
Lab
Western blot - Anti-Aurora B antibody [EP1009Y] (AB45145)
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab45145 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution ab133406
Lanes 1 - 2:
Western blot - Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/1000 dilution
Lanes 3 - 4:
Western blot - Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/5000 dilution
Lanes 5 - 6:
Western blot - Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/10000 dilution
Lanes 7 - 8:
Western blot - Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/50000 dilution
Lanes 9 - 10:
Western blot - Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/75000 dilution
Lanes 1, 3, 5, 7 and 9:
HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg
Lanes 2, 4, 6, 8 and 10:
HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate Nocodozole Stimulated at 10 µg
Secondary
All lanes:
Western blot - VHH Single Domain Anti-Rabbit IgG Fc (HRP) (<a href='/products/secondary-antibodies/vhh-single-domain-rabbit-igg-fc-hrp-ab191866'>ab191866</a>) at 1/10000 dilution
Predicted band size: 39 kDa
Observed band size: 39 kDa
true
Exposure time: 8min
- OI-RD Scanning
Unknown
OI-RD Scanning - Anti-Aurora B antibody [EP1009Y] (AB45145)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
- WB
CiteAb
Western blot - Anti-Aurora B antibody [EP1009Y] (AB45145)
Aurora B western blot using anti-Aurora B antibody [EP1009Y] ab45145. Publication image and figure legend from Chuang, M. J., Wu, S. T., et al., 2013, PLoS One, PubMed 24023871.
ab45145 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab45145 please see the product overview.
HDACI induced G2/M phase cell cycle and growth inhibition in prostate cancer cells via distinct mechanisms.(A) LBH589 had a dose-dependent effect on growth inhibition in prostate cancer cell lines. The cell lines were treated with 50, 75, 100, and 150 nM of LBH589. Cell survival was measured using MTT assay as described in the Materials and Methods section. Graphs compared the percentage of growth inhibition to vehicle control at 24 (upper) and 48 (lower) hours. (B) LBH589 induced G2/M cell cycle arrest. All cell lines were treated with LBH589 or vehicle control for 24 h. The cell cycles were analyzed by PI-staining and flow cytometry according to DNA content. The increased percentages of G2/M cells were compared to that of vehicle control. (C) LBH589 induced apoptosis in PC-3 and LNCaP cells. Both cell lines were treated with 75nM LBH589 or vehicle control for 24 (upper) and 48 (lower) h. The percentages of apoptotic cells were analyzed by counting the population of DNA fragmentation by flow cytometry. (D–E) HDACIs induced Aurora kinase degradation found in PC-3 but not in LNCaP. PC-3 and LNCaP cells were treated with different HDACIs at indicated concentrations of LBH589, SAHA and SBHA for 24 h and cell lysates were analyzed by western blot using the indicated antibodies. (F) Profile of proteins regarding progression of G2/M cell cycle. The cells were treated with different dosages of LBH589 for 24 h. The lysate was analyzed by western blot.
false
反应性数据
产品详情
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
性能和储存信息
形式
纯化工艺
存储溶液
运输条件
推荐的短期储存条件
推荐的长期储存条件
分装信息
储存信息
补充信息
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Aurora B kinase functions to ensure proper chromosome alignment segregation and cytokinesis during mitosis and meiosis. It phosphorylates various substrates to facilitate processes like correction of kinetochore-microtubule attachments and regulation of the mitotic checkpoint. As a part of the CPC Aurora B acts in coordination with other proteins to control these cellular events ensuring that cells divide accurately and safely.
Pathways
Aurora B integrates into the cell cycle and mitotic pathways operating closely with the spindle assembly checkpoint. It interacts with proteins like CENP-A and CENP-E ensuring error-free chromosome segregation. Aurora B's activity within these pathways is critical for maintaining genomic stability and preventing aneuploidy a condition linked to improper chromosome number.
产品实验方案
- Visit the General protocols
- Visit the Troubleshooting
靶点信息
文献 (32)
Recent publications for all applications. Explore the full list and refine your search
Nature communications 16:7832 PubMed40846865
2025
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 16:1583 PubMed39939315
2025
Applications
Unspecified application
Species
Unspecified reactive species
The EMBO journal 42:e111500 PubMed36530167
2022
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 24:317 PubMed35949592
2022
Applications
Unspecified application
Species
Unspecified reactive species
BMC cancer 22:666 PubMed35715760
2022
Applications
Unspecified application
Species
Unspecified reactive species
Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 41:27-43 PubMed35378002
2022
Applications
Unspecified application
Species
Unspecified reactive species
Human cell 35:678-693 PubMed35088239
2022
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 23:164 PubMed35069845
2022
Applications
Unspecified application
Species
Unspecified reactive species
Proteomics 22:e2100141 PubMed34932872
2022
Applications
Unspecified application
Species
Unspecified reactive species
Molecular carcinogenesis 60:644-657 PubMed34169564
2021
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com